Daxor Corporation

NasdaqCM:DXR Stock Report

Market Cap: US$54.0m

Daxor Past Earnings Performance

Past criteria checks 4/6

Daxor has been growing earnings at an average annual rate of 15.7%, while the Medical Equipment industry saw earnings growing at 15.3% annually. Revenues have been declining at an average rate of 27.6% per year. Daxor's return on equity is 20%, and it has net margins of 34359.2%.

Key information

15.71%

Earnings growth rate

10.85%

EPS growth rate

Medical Equipment Industry Growth8.90%
Revenue growth rate-27.62%
Return on equity19.98%
Net Margin34,359.17%
Last Earnings Update31 Dec 2025

Recent past performance updates

Recent updates

Seeking Alpha Aug 25

Daxor reports Q2 results

Daxor press release (NASDAQ:DXR): Q2 The increase in revenue of 92.6 percent in the Company’s operating division represents strong strides in the commercialization of its BVA-100. As of June 30, 2022 the company held net assets of $19,615,712 or $4.85 per share, a 35.3 percent increase versus the same period in the prior year.
Seeking Alpha Jul 21

Daxor partners with Medaxiom to advance awareness of blood volume diagnostic

Daxor (NASDAQ:DXR) said it had partnered with Medaxiom to advance awareness and adoption of Daxor’s blood volume diagnostic. "With heart failure diagnosis continuing to increase, access to accurate blood volume testing will transform the way care decisions are made,” said Joe Sasson, MedAxiom’s EVP of Ventures.
Analysis Article Mar 08

Daxor's (NASDAQ:DXR) Earnings Aren't As Good As They Appear

We didn't see Daxor Corporation's ( NASDAQ:DXR ) stock surge when it reported robust earnings recently. We decided to...
Analysis Article Feb 27

A Look At The Fair Value Of Daxor Corporation (NYSEMKT:DXR)

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Daxor Corporation...

Revenue & Expenses Breakdown

How Daxor makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:DXR Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 250910
30 Sep 250510
30 Jun 250210
31 Mar 250110
31 Dec 240120
30 Sep 240110
30 Jun 240210
31 Mar 240110
31 Dec 230010
30 Sep 230210
30 Jun 230410
31 Mar 230510
31 Dec 220510
30 Sep 220510
30 Jun 220410
31 Mar 220510
31 Dec 210510
30 Sep 210310
30 Jun 210010
31 Mar 210-110
31 Dec 200-210
30 Sep 200-310
30 Jun 200-400
31 Mar 200-200
31 Dec 190000
30 Sep 190000
30 Jun 190000
31 Mar 190000
31 Dec 180-100
30 Sep 180-100
30 Jun 181-100
31 Mar 181-100
31 Dec 171-100
30 Sep 171-100
30 Jun 171-100
31 Mar 171000
31 Dec 161100
30 Sep 161-100
30 Jun 161-300
31 Mar 161-600
31 Dec 151-900
30 Sep 151-700
30 Jun 151-500

Quality Earnings: DXR has a high level of non-cash earnings.

Growing Profit Margin: DXR's current net profit margins are higher than last year .


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: DXR has become profitable over the past 5 years, growing earnings by 15.7% per year.

Accelerating Growth: DXR's earnings growth over the past year (1609.7%) exceeds its 5-year average (15.7% per year).

Earnings vs Industry: DXR earnings growth over the past year (1609.7%) exceeded the Medical Equipment industry 14.8%.


Return on Equity

High ROE: DXR's Return on Equity (20%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/15 09:07
End of Day Share Price 2026/06/15 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Daxor Corporation is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Frank TakkinenLake Street Capital Markets, LLC
Scott HenryRoth Capital Partners